1. 1. Siegel RL, Miller KD, Jemal A. Cancer statistics. CA Cancer J Clin 2015 Jan-Feb;65(1):5-29. doi: 10.3322/caac.21254
2. 2. Karaman M. Pankreatik kanserde susturulan CA9 ve TSPAN8 genlerinin etkilerinin in vitro ve in vivo olarak araştırılması. Doktora Tezi. Balıkesir: Balıkesir Üniversitesi Fen Bilimleri Enstitüsü, Biyoloji Anabilim Dalı, 2018.
3. 3. Steinberg W. The clinical utility of the CA 19-9 tumor-associated antigen. Am J Gastroenterol 1990 Apr;85(4):350-5.
4. 4. Goonetilleke KS, Siriwardena AK. Systematic review of carbohydrate antigen (CA 19-9) as a biochemical marker in the diagnosis of pancreatic cancer. Eur J Surg Oncol. 2007 Apr;33(3):266-70. doi: 10.1016/j.ejso.2006.10.004.
5. 5. Boone BA, Steve J, Zenati MS, Hogg ME, Singhi AD, Barlett DL, Zureikat AH, Bahary N, Zeh HJ. Serum CA 19-9 response to neoadjuvant therapy is associated with outcome in pancreatic adenocarcinoma. Ann Surg Oncol 2014 Dec;21:4351-8. doi: 10.1245/10434-014-3842-z.